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BACKGROUND: Triple negative breast cancer (TNBC) is a breast cancer subtype with negative expressions of estrogen receptors (ER), progesterone 
receptors (PR) and Her-2 protein receptors. This subtype 
exhibits aggressive behavior and poor prognosis since it 
is unresponsive to hormonal and Her-2 targeted therapy. 
The identification of clinicopathological characteristics and 
their prognostic values will provide guidance in developing 
effective treatment. This study was performed to analyze 
the clinicopathological characteristics and prognostic 
significance in Indonesian TNBC. 
METHODS: Forty paraffin-embedded tissues of TNBC, 
stage I to IIIA, dating from 2008 to 2010 in Dr. Sardjito 
Hospital, were enrolled. Survival follow-up was done from 
January 2008 to June 2013. The samples were immunostained 
with ER, PR and Her-2 monoclonal antibodies to determine 
the TNBC subtypes. The clinicopathological characteristics 
were statistically analyzed. The survival was analyzed using 
the Kaplan Meier method. The Cox proportional hazards 
model was used for multivariate analysis.
RESULTS: Mean age of TNBC patients was 51.42±11.72 
years old, whereas the mean of tumor size was 5.4±2.92 cm. 
Lymph node metastasis was found in 70% of cases. Number 
of locally advanced samples (IIIA) was 37.5%, while 
moderate to high grade samples were 95%. Number of still 
alive patients at the end of the study was 55%. Number 
of patients that still alive up to the end of the study was 
45.50%. Lymph node was an independent prognostic factor 
for survival of TNBC patients as positive status of lymph 
node increases the death risk to 6 times higher (p=0.02, 
RR=6.6). However, after being adjusted with age and stage, 
lymph node status was suggested as a modifier effect for the 
survival of TNBCs patients (RR=0.19).
CONCLUSION: Indonesian TNBC patients were mostly 
found already with large tumor size, lymph node metastasis, 
high pathological grade and relatively young age. Lymph 
node status serves as a modifier effect for the survival of 
Indonesian TNBC. 
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Abstract
Introduction
Triple negative breast cancer (TNBC) is described as 
a molecular subtypes of breast cancer that showed no 
expression of estrogen receptors (ER), progesterone 
receptors (PR) and Her-2 protein receptors.(1) It has 
been associated with African-American race, deprivation 
status, younger age at diagnosis, familial breast cancer 
and breast cancer gene (BRCA)1 mutation.(2-4) TNBC 
is clinicopathologically aggressive, associated with large 
tumor size, lymph node metastasis and high pathological 
grade, giving poor prognosis.(5)
 TNBC is unresponsive to endocrine therapy or other 
available targeted agents. Thus, chemotherapy has become 
standard treatment for TNBC.(6,7) TNBC is partly a 
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basal-like subtype with the increased expression of basal 
cytokeratins, such as cytokeratin (CK) 5/6, CK17 and 
epidermal growth factor receptor (EGFR). High recurrence 
and poor response to chemotherapy in TNBC are probably 
due to the presence of basal-like cancer.(8) New effective 
treatment strategies for TNBCs are urgently needed, and 
anti-EGFR treatment is challenging to be used as targeted 
therapy against TNBC.(9,10)
 The latest epidemiologic study in Asian population 
showed that breast cancers cases in Indonesia was reported 
to be 49,998 cases in 2012 (11), in which theoritically 15-
25% of it is triple negative subtype. TNBC data in Indonesia 
is rarely available, however it was mentioned to be occured 
in 25% of all cases in a clinicopathologic corellation 
study of breast cancer subtypes (12), and mostly occured 
in intermediate to high grade tumor. TNBC in Indonesia 
also reported to be associated with high relative death risk.
(13) Survival study of TNBC in Indonesian population 
was reported in locally advanced TNBC with disease free 
survival at 5 years 11.4%.(14)
 Median time to relapse or death of TNBC patients 
are shorter than all other subtypes, and their five-year 
survival rates also tend to be lower. The five-year overall 
survival of TNBC patients was 74.5%. A study of 269 
TNBC subjects at the Institute of Oncology Ljubljana 
reported that in univariate analysis, age, nodal status, tumor 
size and lymphovascular invasion contributed significant 
impact on survival rate. Meanwhile in multivariate analysis, 
results showed that only nodal status was the independent 
prognostic factor for overall survival.(6) 
 Prognostic factors and markers are essential to be 
identified in order to choose high and low risk subsets of 
TNBC patients for better therapy approaches since TNBC 
subtypes may give different response againts specific agents. 
This study was performed to analyze the clinicopathological 
characteristics and prognostic significance of TNBC in an 
Indonesian population.
Methods
Research design of this study was a retrospective cohort 
study, with follow-up of the survival of the patients. 
Clinicopathological parameters, including age, tumor size, 
histopathological grade, staging, lymph node status were 
evaluated in this study. This study was ethically approved by 
the Institutional Review Board of the Faculty of Medicine, 
Public Health and Nursing, Universitas Gadjah Mada 
(Ref: KE/FK/248/EC 2014). Biopsy samples containing 
small focus of tumor were excluded. Tumor grading was 
determined based on morphological features, classified 
into low, moderate and high grade, according to the World 
Health Organization (WHO) classification system. Lymph 
node status was grouped into negative and positive lymph 
node metastasis. Meanwhile, cancer staging was determined 
using the TNM system.(15) Favorable prognostic factor 
criteria were patients with age >50 years old, size ≤2 cm, 
low grade, no lymph node metastasis and an early stage of 
cancer (stage I-II), while criteria for unfavorable prognostic 
factors were patients with age ≤50 years old, size >2 cm, 
positive lymph node metastasis, and locally advanced stage 
of cancer (stage IIIA). 
 The follow-up of patients was done in order to 
collect survival information, determined by weeks still 
alive. Survival information was collected from January 
1, 2008 to June 30, 2013. Triple negative status was 
determined by immunohistochemical (IHC) methods using 
following monoclonal antibodies: 6F11 anti-ER with 1:50 
dilution (Biocare, Birmingham, UK), PGR636 PR with 
1:50 dilution (Biocare), CB11 Her-2 with 1:100 dilution 
(Biocare), Chromogen 3,3' Diaminobenzidine (DAB) and 
Hematoxylin Mayer counter stained. ER and PR staining 
were considered positive by strong nuclei reactivity in >1% 
of tumor cells.(16) Her-2 staining was considered positive 
by strong membrane expression in >30% of tumor cells.
(17) TNBC subtype was determined when tumors were 
negatively stained with ER, PR and Her-2. 
 Correlations between each prognostic 
clinicopathological factor for survival of TNBC were 
analyzed using bivariate analysis. Survival was analyzed 
using product limit of Kaplan Meier estimator. Log-rank 
test with significance level of <0.05 was used to compare 
between favorable and unfavorable prognosis. Multivariate 
analysis was conducted to determine the prognostic 
values. To control for other prognostic values, analysis of 
Proportional Hazards (Cox) regression was performed.
Results
Among 40 cases of TNBC studied, the mean of patient age 
was 51.42±11.72 years old, and mean of tumor size was 
5.4±2.92 cm. Lymph node metastasis was found in 70% of 
all cases. Number of locally advanced stage (IIIA) samples 
was 37.50%, and samples with moderate to high grade were 
95%. Number of patients that were still alive at the end of 
the study was 55%. Characteristics of the TNBC samples 
are shown in Table 1.
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n (%) Mean±SD (Range)
51.22±11.72 (32-81)
≤ 50 years old  22 (50%)
> 50 years old 22 (50%)
5.40±2.9 (1-15)
< 2 cm 5 (12.5%)
≥ 2 cm 35 (87.50%)
Negative 12 (30%)
Positive 28 (70%)
Well 2 (5%)
Moderate-high 42 (95%)
Early 25 (62.50%)
Locally advanced 15 (37.50%)
Dead 18 (45%)
Alive 22 (55%)
185.92±57.44 (54-278) 
Staging
Status
Survival (weeks)
Characteristics
Age (years old)
 Size (cm)
Lymph node status
Histological grade
Table 1. Characteristics of TNBC patient.
 Univariate analysis was performed and it demonstrated 
that age (p=0.05) and lymph node status (p=0.02) were 
significantly associated with survival status of TNBC 
patients. Meanwhile, other clinicopathological factors, 
≤ 50 years old   6 (30%) 14 (70%)
> 50 years old 12 (60%)   8 (40%)
< 2 cm   3 (60%)   2 (40%)
≥ 2 cm 15 (42.85%) 20 (57.15%)
Negative   2 (16.16%) 10 (83.84%)
Positive 16 (57.14%) 12 (42.86%)
Well   2 (100%) 0 (0%)
Moderate-high 17 (44.73%) 21 (55.27%)
Early 9 (36%) 16 (64%)
Locally advance 9 (60%)   6 (40%)
Histological grade
Relative Risk 
95% CI
Staging
0.45 0.94 (0.84-1.06)
0.12 2.67 (0.72-9.95)
0.28 (0.07-1.06)
0.4 0.50 (0.07-3.38)
0.02 6.67 (1.23-36.23)
Size
Lymph node status
Characteristics
Status
p -value
Death (%)          Alive (%)
0.05
Age
Table 2. Clinicopathologic factors analysis of TNBC subtype for survival.
such as size, histopathological grade and staging were not 
significantly associated (Table 2). 
 Number of patient that  still alive up to the end 
of the study was 45.50%. Lymph node was suggested as 
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an independent prognostic factor for survival of TNBC 
patients.  Positive status of lymph node was demonstrated 
to increase the death risk until 6 times higher (p=0.02, 
RR=6.6). However, adjustment was performed with age 
and stage, lymph node status was proposed as a modifier 
effect for the survival of TNBCs patients (RR=0.19) (Table 
3, Figure. 1). 
Death (%)       Alive (%)
≤ 50 years old     6 (30%)          14 (70%)
> 50 years old   12 (60%)              8 (40%)
Negative   2 (16.16%)          12 (83.84%)
Positive 16 (57.14%)           12 (42.86%)
Early 9 (36%) 16 (64%)
Locally advance 9 (60%) 6 (40%)
Staging
Adjusted
(95% CI)
Unadjusted
(95% CI)
2.21(0.87-5.55)
0.02 6.67 (1.23-36.23) 0.19 (0.04-0.84)
0.12 2.67 (0.72-9.95)   0.82 (0.32-2.14)
Lymph node status
Prognostic factors
Survival
p -value
0.05 0.28 (0.07-1.06)
Age
Table 3. Independent predictor factors analysis of TNBC subtype for survival.
Discussion
TNBC has been described as the most aggressive subtype 
of breast cancer, characterized by the absence expression 
of estrogen, progesterone and Her-2 receptors. This 
subtype of breast cancer does not respond with targeted 
therapy, resulting in chemotherapy selected as the only 
choice of treatment. TNBC is often associated with poor 
clinicopathological outcome with a high mortality rate.
(13,18,19)
 A previous study of breast cancer in Indonesia using 
a large sample size (247 patients) reported that the mean 
age of TNBC patients was 51.84 years old, almost similar 
with the result of this study.(20) A study of TNBC patients 
in the Institute of Oncology Ljubljana showed that median 
age of TNBC patients was 55.3 year old, with the majority 
of patients (60.3%) already in the postmenopausal phase.(6) 
Similar results were found by a study in Busan Paik Hospital, 
showing that the median age of TNBC patients was 54 years 
old.(21) Older-aged individuals compose nearly 20% of 
TNBC cases.(22) A study in Malaysia showed that median 
age for both TNBC and non-TNBC subtypes were 59 years 
old. The older median age of TNBC patients are suspected to 
be associated with prior family history of breast cancer and 
accredited to the prior use of endocrine therapy. Endocrine 
therapy has been previously described to minimize the risk 
of ER positive breast cancer.(5) However, another previous 
study in Malaysia reported that TNBC most likely occurred 
at younger ages, with mean and median age of patient of 
49.4 and 48 years old, respectively.(1) Some studies in 
Kuwait and India also demonstrated similar results, with the 
median age of TNBC patients of 48 years old (23,24) and 
46.12 years old, respectively (25).
 Different spectrum of certain biological variations 
may partly elaborate the age-related discrepancy in the 
survival of TNBC. For instance, BRCA mutations were 
reported to be more frequent in young breast cancer patients 
and exhibited poorer prognosis.(4,26) However, older-
aged women with TNBC showed reduced overall survival 
compared with the younger individuals. Senility seems to 
be associated with worse conditions and co-morbidities that 
need additional attention and monitoring that complicate the 
clinical management and results with an increased risk of 
therapy-related adverse events.(26)
 According to previous study, the frequency of TNBC 
in Indonesian population was quite high, accounted for 
29.33%.(13) Other studies also showed high prevalence 
of TNBC patients among African-America patients (39%) 
and Indian patients (31%). Multiple factors may affect this 
condition, including early age onset of breast cancer; lifestyle 
factors, such as diet and obesity; reproductive factors, such 
as multi-parity; socio-economic status; screening behaviors 
and genetic susceptibility.(3,27,28)
 Most of the TNBC cases in this study demonstrated 
large tumor size, with 87.5% >2 cm and the mean tumor 
size of 5.40±2.92 cm. Furthermore, 70% of the patients 
showed lymph node metastasis and 95% of the cases 
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Figure 1.  Survival analysis of TNBC patients 
based on lymph node status. The green 
line indicates patients with negative lymph 
node status. The blue line indicates patients 
with positive lymph node status. Patients 
with negative lymph node status show higher 
survival rate compare to patients with positive 
lymph node status. 
displayed moderate to poor histological grade. These results 
were similar to other studies showing that large tumor size 
indicated an aggressive behavior which was associated with 
more positive axillary lymph node, higher clinical stage, 
higher histological grade and poorer prognosis.(23,24,29-
31) TNBC patients also showed worse overall survival than 
non-TNBC patients.(32) Biological characteristics of TNBC, 
such as increase cell proliferation, poor differentiation, 
imbalances of recurrent copy number, and tumor protein 
(TP)53 mutations, contribute to the aggressive nature of this 
type of tumor.(33,34)
 TNBC is frequently used as a substitute identifier 
of the aggressive basal breast cancer subtype since both 
basal-like and TNBC are related to poor clinical outcomes. 
The two subtypes share some similarities; however, they 
are not biologically-identical. The basal subtype shows an 
apparent expression of basal markers, such as CK5/6, CK17 
and EGFR.(27,35-37) High recurrent and poor response 
to chemotherapy in TNBC may be caused by the presence 
of basal-like subtype.(8) Previous study found that the 
frequency of basal-like subtype in Indonesia was quite high, 
with 58.8%. In this study, based on survival follow-up, 45% 
of TNBC patients died.(20) The high number of mortalities 
of Indonesian TNBC patients is probably due to the high 
frequency of basal-like subtype of breast cancer.
 In this study, positive status of lymph node increased 
the death risk to 6 times higher and it  was proposed as a 
modifier effect to the survival of TNBCs patients since the 
other causes of TNBCs patients death had not been deeply 
observed, such as chemotherapy effect, patient`s response 
immune and other comorbid diseases. Therefore, further 
research  using  larger  samples  is  necessary  to  be  done, 
in order to give better insight regarding this matter. One 
previous study in China found that tumor size and lymph 
node status were significant prognostic factors for 7 year 
disease free survival and overall survival of TNBC patients.
(38) Another study in China also supported that in TNBC 
patients with adjuvant chemotherapy of fluorouracil, 
epirubicin, and cyclophosphamide lymph node status was 
an independent prognostic factor of overall survival and 
disease free survival.(39) However, in TNBC cases with 
lymph node metastasis, the prognosis was not greatly 
affected by the number of positive lymph nodes. It is 
possible apart from lymphatic metastasis, hematogenous 
metastasis also has an important role in TNBC progression, 
even at an early stage.(40)
 Prior studies concluded that lymph node ratio (LNR) 
was the independent predictor of overall survival of TNBC 
patients. The LNR is defined as total number of positively 
involved lymph nodes divided by total number of analyzed 
lymph nodes. It predicts survival rate more accurately 
compared to pN staging. Breast cancer staging system 
highlights the prognostic significance of the absolute number 
of positive lymph nodes. The use of LNR may standardize 
the staging determination and provide guidance of adjuvant 
therapy administration.(41-43)
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Conclusion
This TNBC study in an Indonesian population showed that 
TNBC patients were commonly presented with large tumor 
size, lymph node metastasis, high histopathological grade 
and relatively young age. Lymph node status was proposed 
as a modifier effect for the survival of  TNBC patients in 
Indonesian population.
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